- Home
- ILLU vs AVIR Comparison
ILLU vs AVIR Comparison
Compare ILLU & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ILLU | AVIR |
|---|---|---|
| Founded | 2025 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 312.0M | 334.5M |
| IPO Year | 2025 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ILLU | AVIR |
|---|---|---|
| Price | $9.98 | $4.28 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 133.7K | ★ 293.8K |
| Earning Date | N/A | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $351,367,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.90 | $2.87 |
| 52 Week High | $10.01 | $6.45 |
Technical Indicators
Market Signals| Indicator | ILLU | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 54.85 | 42.21 |
| Support Level | $9.97 | $4.06 |
| Resistance Level | $10.00 | $4.63 |
| Average True Range (ATR) | 0.00 | 0.25 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 28.77 | 50.00 |
Price Performance
Historical ComparisonAbout ILLU Illumination Acquisition Corp I Class A Ordinary Shares
Illumination Acquisition Corp I is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.